Baidu
map

糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Medicine：甘油三酯血糖指数可以预测糖尿病肾病的发生

2020-06-16 MedSci原创 MedSci原创

糖尿病肾病甘油三酯血糖
关注

胰岛素抵抗通常是2型糖尿病发病的关键因素。甘油三酯葡萄糖（TyG）指数是胰岛素抵抗的标志物，也与2型糖尿病患者的肾病风险有关。本研究旨在探讨TyG指数与2型糖尿病患者中新诊断的活检证明的糖尿病肾病风险

胰岛素抵抗通常是2型糖尿病发病的关键因素。甘油三酯葡萄糖（TyG）指数是胰岛素抵抗的标志物，也与2型糖尿病患者的肾病风险有关。本研究旨在探讨TyG指数与2型糖尿病患者中新诊断的活检证明的糖尿病肾病风险之间的关联和潜在阈值。

 

研究人员实施了一项嵌套式病例对照研究，纳入950例活检证明的糖尿病肾病事件病例，以及通过风险集抽样方法选取的4750例经治疗的2型糖尿病患者作为对照。通过条件逻辑回归模型研究了校正年龄、性别、血压和其他主要心血管危险因素后，TyG指数与新诊断活检证明的糖尿病肾病后续风险之间的剂量-反应关系。

 

结果发现，TyG指数与新诊断活检证实的糖尿病肾病风险之间存在非线性关系，TyG的潜在阈值为9.05-9.09。通过空腹血糖和甘油三酯水平的分析也发现了与相同阈值的类似关系。

 

TyG指数可能是预测经治疗的2型糖尿病患者新发活检证实的糖尿病肾病的预后因素。在2型糖尿病患者中，TyG指数高于9.05-9.09可能是识别糖尿病肾病高危个体的预后阈值。需要进一步的验证研究。

 

原始出处：

 

Jin Shang, Dahai Yu, et al., The Triglyceride Glucose Index Can Predict Newly Diagnosed Biopsy-Proven Diabetic Nephropathy in Type 2 Diabetes: A Nested Case Control Study. Medicine (Baltimore). 2019 Nov;98(46):e17995. doi: 10.1097/MD.0000000000017995.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1859048, encodeId=ee8e185904804, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Mar 09 08:56:49 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773855, encodeId=df9c1e7385552, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 30 13:56:49 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577720, encodeId=f91415e77202d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610529, encodeId=0d60161052917, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043178, encodeId=0a6e10431e8bc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 21:56:49 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2021-03-09 jeanqiuqiu

    #DIC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1859048, encodeId=ee8e185904804, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Mar 09 08:56:49 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773855, encodeId=df9c1e7385552, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 30 13:56:49 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577720, encodeId=f91415e77202d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610529, encodeId=0d60161052917, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043178, encodeId=0a6e10431e8bc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 21:56:49 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2021-03-30 kalseyzl

    #CIN#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1859048, encodeId=ee8e185904804, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Mar 09 08:56:49 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773855, encodeId=df9c1e7385552, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 30 13:56:49 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577720, encodeId=f91415e77202d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610529, encodeId=0d60161052917, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043178, encodeId=0a6e10431e8bc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 21:56:49 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-06-18 ms1692212821629096

    #Medicine#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1859048, encodeId=ee8e185904804, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Mar 09 08:56:49 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773855, encodeId=df9c1e7385552, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 30 13:56:49 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577720, encodeId=f91415e77202d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610529, encodeId=0d60161052917, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043178, encodeId=0a6e10431e8bc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 21:56:49 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-06-18 ms3994565386320060

    #Med#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1859048, encodeId=ee8e185904804, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Mar 09 08:56:49 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773855, encodeId=df9c1e7385552, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 30 13:56:49 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577720, encodeId=f91415e77202d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610529, encodeId=0d60161052917, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 09:56:49 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043178, encodeId=0a6e10431e8bc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 21:56:49 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-06-16 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

在没有2型糖尿病射血分数降低（HFrEF）的心力衰竭患者中，Farxiga将新发糖尿病的风险降低了32％。

《柳叶刀》、NEJM两大**医学期刊发文：新冠病毒或致健康人新发糖尿病

迄今为止的临床观察表明，COVID-19与糖尿病之间存在双向关系。

甜食-快餐饮食易致糖尿病！杭州研究

近日，浙江大学研究人员发表的一项基于社区的横断面研究表明，以蔬菜-水果为主的饮食模式可显着降低胰岛素抵抗、糖尿病和腹型肥胖风险，而以甜食-快餐为主的饮食模式则显着增加上述代谢疾病风险，以米饭-肉类或海

Circulation：抗血小板+抗凝对糖尿病合并心血管疾病患者的联合疗效

冠状动脉疾病或外周动脉疾病患者通常合并糖尿病。这类患者未来发生血管事件的风险很高。

Diabetes Obes Metab：糖尿病对SARS-CoV-2感染严重程度和致命性的影响

该研究的结果提供了新的证据表明糖尿病与较高的COVID-19严重性和致命性风险相关。因此，SARS-CoV-2感染的糖尿病患者应考虑加强监护和降糖治疗。

J Diabetes Investig：Empagliflozin治疗2型糖尿病和心血管疾病患者的效果

在EMPA-REG OUTCOME®试验中，在标准护理中加入empagliflozin可改善2型糖尿病和已建立的心血管疾病患者39%的临床相关肾脏结果，延缓慢性肾脏疾病的进展，减少白蛋白尿。该

Baidu
map
Baidu
map
Baidu
map